Longevity Supplement Stacks: What 4 Public Figures Take

Longevity supplement stacks are daily combinations of dietary nutrients and prescription medications assembled by researchers and clinicians to target specific biological mechanisms of aging. While prominent figures in preventive medicine publish their personal regimens, these routines reflect individual biological markers, subjective targets, and personal medical oversight. Examining these public disclosures provides insight into the clinical compounds under discussion without treating an individual protocol as a universal standard. A physician reviews validated biomarkers to guide you toward therapies supported by clinical evidence.

What Peter Attia and Andrew Huberman Disclosed on Their Own Podcast

In a July 2024 episode of the Huberman Lab podcast, Peter Attia and Andrew Huberman conducted a detailed review of their personal supplementation choices and the biological reasoning behind them (Huberman and Attia^1). Both speakers differentiated between commercial marketing claims and their own daily practices, outlining exact compounds and specific prescriptions.

Peter Attia stated clearly on the record that he does not take nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). Instead of over-the-counter NAD+ boosters, Attia disclosed taking rapamycin, an mTOR-inhibitor prescription drug, for approximately six years. He described a dosing schedule of roughly 8 mg once per week, accompanied by periodic breaks due to recurrent side effects such as mouth sores. Mechanistically, rapamycin targets the mechanistic target of rapamycin (mTOR) complex, a nutrient-sensing pathway involved in cellular growth, protein synthesis, and autophagy.

Attia also disclosed a targeted list of prescription pharmaceutical agents focused on cardiovascular risk and metabolic regulation. These include a PCSK9 inhibitor and bempedoic acid to manage apolipoprotein B and low-density lipoprotein particle counts, alongside an SGLT2 inhibitor, which regulates renal glucose handling and glycemic stability. Alongside these prescription medications, Attia listed his daily dietary supplements:

• Vitamin D at a dose of 5,000 IU daily
• Methylfolate and methyl B12 for cellular methylation pathways
• Magnesium L-threonate and ashwagandha taken specifically for sleep support
• Creatine monohydrate at a stable dose of 5 g daily for muscular and cognitive energy support
• EPA and DHA fish oil capsules to support lipid profiles
• AG1 taken most mornings
• An LMNT electrolyte packet consumed daily
• Pendulum probiotic formulations, specifically the Glucose Control, Polyphenol, and Akkermansia strains

Andrew Huberman disclosed a distinct protocol during the same conversation, outlining compounds selected for energy, sleep support, and personal performance. Huberman addressed NAD+ supplementation directly, stating: "I'll go on record now saying that I take NMN." He described taking approximately 1,500 mg of sublingual NMN first thing in the morning, noting that his selection was "mostly based on cost." He mentioned that he sometimes takes NR as well. Huberman attributed a subjective energy improvement to NMN use, though he explicitly stated that he does not believe the compound extends human lifespan. In addition to oral precursors, Huberman disclosed having received five to six NAD+ intravenous infusions, describing the physical sensation of the infusion drip itself as unpleasant while reporting that he felt better following the session.

Huberman's wider daily intake includes dietary extracts, amino acids, and micronutrients:

• AG1 taken at one to three servings daily
• Fish oil providing more than 1 g daily of EPA
• Vitamin D3 at roughly 5,000 IU daily, with intake fluctuating between 3,000 and 7,000 IU based on blood testing
• Methyl B12 to support methylation pathways
• Tongkat ali taken as one capsule early in the day
• Green tea capsules, alongside yerba mate and coffee as primary caffeine sources
• Creatine monohydrate at 10 g daily
• Magnesium threonate taken before bedtime to promote sleep onset
• Apigenin at 50 mg and theanine for evening relaxation
• Inositol taken occasionally at a dose of roughly 900 mg
• Whey protein to meet daily amino acid requirements
• Shilajit taken intermittently
• Experimental 50 mg caffeine tablets for daytime focus

Huberman also reported that he previously used nicotine gum but has completely stopped using it. Regarding resveratrol, neither Attia nor Huberman discloses personally taking the compound. Both speakers evaluated resveratrol strictly as an experimental sirtuin-activator candidate evaluated within the National Institute on Aging's Interventions Testing Program, noting that the trial failed to demonstrate an extension of lifespan in mice. Readers can examine the published human data on sirtuin activation in our analysis of resveratrol clinical trials. Consulting a physician allows you to evaluate whether specific longevity compounds align with your metabolic markers.

What David Sinclair Has Said About His Own Routine

David Sinclair, a Harvard geneticist and researcher in the biology of aging, disclosed his personal supplementation habits during an interview on the FoundMyFitness podcast hosted by Dr. Rhonda Patrick (Sinclair^2). Sinclair's research career has centered on the role of sirtuins, a family of NAD+-dependent enzymes that regulate epigenetic modifications, DNA repair, and mitochondrial function.

Sinclair disclosed taking two primary molecules to support these cellular pathways: resveratrol and NMN. Describing his daily intake of resveratrol, Sinclair stated: "It is a gram of resveratrol, whatever I pour out into my yogurt." He explained that he mixes roughly 1 gram of resveratrol directly into yogurt because the polyphenol is fat-soluble, requiring dietary lipids to facilitate gastrointestinal absorption. Alongside resveratrol, Sinclair disclosed taking approximately 1 gram of NMN daily, consumed as an oral capsule in the morning with coffee.

During the interview, Sinclair noted that he consumes both compounds alongside caffeine. He stated that he "believes" this specific combination aids in managing jet lag and mitigating the effects of poor sleep. This statement represents Sinclair's personal, undemonstrated belief rather than an outcome validated by controlled human clinical trials. While preclinical rodent studies from Sinclair's laboratory explored how resveratrol interacts with SIRT1 and how NMN elevates intracellular NAD+ concentrations, human trials have not confirmed that this combination extends longevity or protects against sleep disruption. Readers can review the clinical evidence regarding oral precursors in our breakdown of NMN supplementation. A clinical consultation provides the diagnostic context necessary to evaluate your personal cellular health without relying on anecdotal protocols.

What Bryan Johnson's Blueprint Protocol Publishes

Bryan Johnson, an entrepreneur focused on biological age reduction, publishes his full daily regimen on his public Blueprint website (Johnson^3). The protocol, known as "Bryan's Free Protocol," details an intensive schedule spanning dietary supplements, prescription medications, caloric restriction, and topical dermatological treatments.

Johnson's published daily supplement list contains a wide selection of branded powders, isolated micronutrients, and botanicals:

• Branded "Longevity Mix" (one scoop daily)
• Creatine monohydrate at 5 g daily
• Microbiome-targeted soluble fibers, including galactooligosaccharides, inulin, and arabinogalactan
• Hydrolyzed collagen peptides taken as 11 g at breakfast and an additional scoop mid-morning
• Branded "Essential Capsules" (two capsules daily)
• Branded "Advanced Antioxidants" (one capsule daily)
• Ashwagandha and rhodiola rosea to modulate perceived stress and cortisol responses
• Omega-3 fatty acids providing 800 mg of combined EPA, DHA, and DPA
• Nicotinamide riboside at 450 mg or NMN at 500 mg, with the protocol alternating between the two NAD+ precursors

Alongside these dietary supplements, Johnson's website separately documents an extensive list of prescription pharmaceuticals, which he categorizes as his "Rx stack." This list includes daily hormone management, metabolic modulators, and cardiovascular agents:

• Thyroid support consisting of Armour Thyroid (60 mg daily) and levothyroxine (100 mcg daily)
• Oral minoxidil, listed as 3.75 mg daily in his primary routine table and 5 mg daily in his hair-specific section, reflecting an internal disagreement between different pages of his own website
• Metformin prescribed at 500 mg, taken on a cyclical schedule of six weeks on followed by six weeks off
• Tadalafil at 5 mg daily
• Empagliflozin (Jardiance), an SGLT2 inhibitor, at 10 mg daily to enhance glucose excretion
• Acarbose, an alpha-glucosidase inhibitor that slows carbohydrate absorption, where the site's own sections disagree by listing 200 mg twice daily in one section and 400 mg daily in another
• Evolocumab (Repatha), a monoclonal antibody PCSK9 inhibitor, described as administered every other week in one location and every two weeks in another, representing the same clinical frequency
• Candesartan, an angiotensin II receptor blocker, listed at 8 mg daily solely within the prescription section

Johnson's protocol also incorporates a topical scalp application. This involves a custom solution containing 7% minoxidil combined with other active ingredients applied every evening, followed by a proprietary peptide serum. On his website, Johnson states that he assembled a dedicated team of medical professionals to oversee his protocol, perform routine diagnostic tests, and manage these prescriptions. This disclosure confirms that his protocol operates under personal medical supervision rather than serving as an open template for the public. Working with a doctor ensures that any pharmaceutical intervention is tailored directly to your physiological needs.

What These Four Regimens Have in Common

Comparing the public disclosures of Attia, Huberman, Sinclair, and Johnson reveals distinct commonalities alongside major biological divergences. The most prominent commonality across all four protocols is the integration of prescription pharmaceuticals alongside over-the-counter dietary supplements. None of these regimens relies purely on vitamins or commercially available longevity blends. Instead, each individual incorporates regulated prescription drugs:

• Attia uses rapamycin, bempedoic acid, PCSK9 inhibitors, and SGLT2 inhibitors.
• Johnson uses metformin, acarbose, empagliflozin, evolocumab, candesartan, thyroid hormones, and minoxidil.
• Huberman and Attia both use prescription compounds or specialized medical procedures, such as supervised intravenous infusions.

These prescription agents are potent drugs designed to alter lipid metabolism, glycemic regulation, cellular growth pathways, and vascular tone. They carry established side effect profiles, including the mouth sores Attia noted with rapamycin and the potential gastrointestinal distress associated with acarbose and metformin. These compounds require individualized diagnostic testing and continuous physician oversight. These public disclosures represent individual choices of public record rather than clinical endorsements or medical recommendations for readers.

The protocols diverge substantially on the cellular pathways they target. Sinclair focuses heavily on the NAD+-sirtuin axis through daily NMN and resveratrol consumption. In contrast, Attia explicitly avoids both NMN and NR, focusing his pharmacological strategy on mTOR inhibition through rapamycin and aggressive lipid lowering via PCSK9 inhibition. Huberman takes NMN for subjective daily energy while expressing skepticism regarding its ability to extend human lifespan. Johnson attempts to modulate multiple longevity hallmarks simultaneously, combining caloric restriction, NAD+ precursors, SGLT2 inhibition, and glucose-absorption blockers.

Notably, none of the four individuals discloses taking urolithin A on the public records cited here, despite commercial interest surrounding its role in mitochondrial autophagy. Readers can evaluate the current clinical literature on mitophagy in our review of urolithin A evidence. Furthermore, these four individuals monitor their biology through personalized testing routines rather than standardized commercial formulas. Navigating preventive health requires evaluating your unique physiological baselines through comprehensive diagnostic testing, as outlined in our overview of longevity medicine protocols. A physician-led consultation provides the appropriate framework to interpret these biomarkers safely.

The Opt Take on Longevity Supplement Stacks

Opt Health approaches preventive longevity medicine through objective diagnostic measurement and individualized physician care. We do not recommend copying public supplement stacks or unmonitored prescription protocols found on the internet. High-profile figures assemble routines based on personal biological markers, subjective performance goals, and dedicated private medical teams. What supports one individual's lipid profile or glycemic control may prove ineffective or hazardous to another person without identical diagnostic indications.

Our care model begins with an advanced blood panel analyzing 55+ biomarkers, establishing your baselines across sex hormones, metabolic health, inflammation, and cardiovascular risk. You review these findings directly with an Opt Health physician during a 1:1 consultation to build a targeted medical protocol based on documented clinical need. We repeat this comprehensive diagnostic panel and physician consultation every 3 to 4 months, allowing your doctor to adjust your prescriptions and supportive therapies as your biomarkers shift. We operate on a direct cash-pay basis, bypassing insurance restrictions while accepting HSA and FSA payments. You can review our diagnostic options across our Opt Health memberships.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.